Larry WittenbergCo-Chair of Life Sciences Practice
Larry Wittenberg is a senior partner in Goodwin Procter’s Technology Companies & Life Sciences Group and Co-Chair of the firm’s Healthcare Technology and Services Practice. He has more than 30 years’ experience representing life science and healthcare technology companies, ranging in size from start-ups to public companies, in corporate and intellectual property transactions and general corporate matters. This work has included numerous venture capital financings, public offerings, mergers and acquisitions, strategic alliances, joint ventures, licenses and technology transfer agreements. Mr. Wittenberg also represents venture capital groups on their investments in life sciences companies and investment banks in connection with public and private financings. Mr. Wittenberg is a key contributor to Goodwin Procter’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. He has structured and negotiated corporate partnering transactions with numerous global pharmaceutical companies. Mr. Wittenberg co-founded the firm’s Life Sciences Practice and previously served as Co-Chair of that practice and as national Co-Chair of Goodwin's Technology Companies & Life Sciences Group.
Work for Clients
Mr. Wittenberg’s practice focuses primarily on biotechnology, medtech and healthcare IT companies. His recent representations include:
- Acetylon Pharmaceuticals, Inc. in its collaborative agreement with Celgene Corporation providing for $100 million in non-dilutive development financing and a buyout option of up to $1.7 billion
- athenahealth, Inc, a provider of cloud-based electronic health records, practice management and care coordination services to doctors and hospitals, in its $293 million acquisition of Epocrates, Inc., a developer and provider of one of the most widely-used clinical information tools for healthcare professionals
- Action Pharma, in the $110 million sale of the rights to develop and commercialize the kidney drug compound AP214 to Abbott Laboratories
- Abide Therapeutics, Inc., in its $430 million collaboration with Merck in the metabolic disease and diabetes fields
Mr. Wittenberg serves on the board of directors of MassBio, an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research.
Mr. Wittenberg is a frequent speaker on corporate collaborations, start-ups and public and private financing, both in industry settings and at the Massachusetts Institute of Technology and other Boston-area universities.
Prior to joining Goodwin Procter, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he co-founded and headed its Life Sciences Practice.
Mr. Wittenberg has been selected for inclusion in U.S. News-Best Lawyers.
- J.D., Harvard Law School, 1979 (cum laude)
- B.A., Cornell University, 1976 (magna cum laude)
Bar and Court Admissions
Mr. Wittenberg is admitted to practice in Massachusetts.